Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Hepato-Biliary

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 7.38 [0.94, 58.05]
1 study · 115 participants
Very low

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes grade 1 ‐ 4 anaemia compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.26 [1, 1.59]
2 studies · 151 participants
Very low

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus cisplatin changes grade 1 ‐ 4 anaemia compared with S‐1 plus cisplatin (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 11.27 [4.41, 28.83]
1 study · 96 participants
Very low

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus vandetanib changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 7.12 [0.9, 56.08]
1 study · 117 participants
Very low